Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

Gastroparesis future or investigational therapies

Introduction

Overview

Overview

Future or investigational therapies

Future or investigational therapies

  • In patients with diabetic gastroparesis, ghrelin and motilin receptors, are the two key pharmacological targets, that have emerged for novel therapeutic options.
  • The intravenously administered cyclic ghrelin analog, TZP-101, was demonstrated to accelerate gastric emptying and improve symptom severity when compared with placebo.
  • When studied in a phase IIa clinical trial, the oral counterpart, TZP-102, showed promise in that significant improvement in symptoms were seen (although there was no change in gastric emptying) after 4 weeks of treatment
  • The follow-up 12-week phase IIb trial 76 failed to demonstrate a benefit; however, and it seems further investigation of this agent is not being pursued.
  • Relamorelin (RM-131) is a synthetic small molecule ghrelin agonist which, when administered as a one-time subcutaneous injection, has been demonstrated to accelerate gastric emptying in patients with diabetic GP.
  • In a 4-week, phase II clinical trial, twice daily relamorelin improved gastric emptying as measured by breath testing and improved subjective vomiting severity as compared with placebo.
  • Other GP symptom measurements were not significantly improved, however, Camicinal (GSK962040) is a small molecule selective motilin receptor agonist that was developed based on the mechanism and molecular structure of macrolide antibiotics.
  • Camicinal improves gastric empting in diabetic GP as demonstrated in several phase I clinical trials 80 and preliminary results of a phase II clinical trial demonstrates significant symptom improvement above placebo.
References

References

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]